EFTR — Effector Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- $1.36m
- -$5.10m
Annual balance sheet for Effector Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 3.43 | 15.2 | 49.7 | 26.3 | 18.4 |
| Prepaid Expenses | |||||
| Total Current Assets | 4.27 | 16.6 | 52.9 | 28 | 19.8 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.823 | 0.126 | 0.257 | 0.352 | 0.193 |
| Other Long Term Assets | |||||
| Total Assets | 5.09 | 16.7 | 54.1 | 29.1 | 20.5 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 18.9 | 8.78 | 3.98 | 25.1 | 25.8 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 18.9 | 15.7 | 36.8 | 25.2 | 26.3 |
| Redeemable Preferred Stock | |||||
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | -13.8 | 0.979 | 17.3 | 3.9 | -5.79 |
| Total Liabilities & Shareholders' Equity | 5.09 | 16.7 | 54.1 | 29.1 | 20.5 |
| Total Common Shares Outstanding |